[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"covid---19\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:covid---19":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,46,74,96,127,150,180,203,224],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100585813","phase-3-dapagliflozin-for-long-covid-syndrome-100585813",false,"NCT06907251","Dapagliflozin for Long COVID Syndrome","DALCO","Inclusion Criteria:\n\n* 18 years of age or older and willing and able to provide informed consent\n* Patients with a history of positive COVID-19 test (polymerase chain reaction or rapid test) or have been diagnosed with COVID-19 by a health care provider.\n* New or persistent symptoms at least 12 weeks from infection and present for at least 8 weeks that is not explained by an alternative diagnosis (64).\n* Women of childbearing potential (WOCBP) who, if sexually active, are willing to use to use at least one highly effective methods of contraception throughout the study.\n\nExclusion Criteria:\n\n* History of diabetes\n* Prior heart failure\n* Weight loss treatment with glucagon-like peptide-1 receptor agonists (e.g. liraglutide, semaglutide)\n* Pregnancy or planned pregnancy in the next 12 months. We will ask WOCBP about the possibility of pregnancy at the time of screening and if so, then pregnancy testing will be offered. If testing is declined in this instance, then they will be excluded from the study.\n* Women who are breastfeeding\n* Severe renal impairment (eGFR\\\u003C30mL\u002Fmin1.73m2)\n* Known history of allergy or hypersensitivity to dapagliflozin\n\nExclusion for optional MRI portion of the protocol:\n\n\\- Any contraindication to MRI","ALL","18 Years",{"count":19,"type":20},192,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","This is a randomized, placebo-controlled study. Patients with long COVID will be randomized to receive dapagliflozin or placebo for 12 months.",[26,27,28],"COVID - 19","Long COVID Syndrome","SARS CoV-2",[30,31,32],"Covid-19","Long Covid syndrome","sars cov-2","NOT_YET_RECRUITING","2026-06-30",{"date":36,"type":37},"2026-07-01","ACTUAL",{"date":39,"type":20},"2026-09-01",{"date":41,"type":20},"2029-06-30",{"name":43,"class":44},"Ottawa Heart Institute Research Corporation","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":45},"100639061","virological-surveillance-of-acute-respiratory-infection-in-primary-health-care-in-metropolitan-france-100639061","NCT07599449","Virological Surveillance of Acute Respiratory Infection in Primary Health Care in Metropolitan France","RS-viro IRA","Inclusion Criteria:\n\n* be seen by a general practitioner or pediatrician participating in the Sentinelles surveillance program;\n* between week 40 (late September-early October) and week 15 (mid-April) of each year\n* have an acute respiratory infection (ARI) as defined below: Sudden onset of fever (or feeling of fever) and respiratory symptoms\n* have given oral consent to participate in this monitoring or, in the case of minors, oral consent given by the child's legal guardian(s) present at the consultation\n\nExclusion Criteria:\n\n* a person who is subject to a court-ordered protective measure;\n* a person who is under guardianship or conservatorship, unless accompanied by their legal guardian or unless the legal guardian objects to their participation;\n* a person who is not in a condition to receive information or give consent.",{"count":54,"type":20},25000,"OBSERVATIONAL","Every year in the fall and winter, numerous respiratory viruses (such as influenza viruses, SARS-CoV-2 (COVID-19), RSV, rhinovirus, and metapneumovirus) circulate in mainland France, causing acute respiratory infections (ARIs). These viruses can cause epidemics of varying severity, requiring close monitoring to determine their circulation levels and adapt public health measures accordingly. In France, ARI surveillance relies on two networks: the Sentinelles network in primary care and the RENAL network in hospitals. The Sentinelles surveillance is conducted in collaboration with Santé publique France, the National Reference Center for Respiratory Infection Viruses (Institut Pasteur and Hospices Civils de Lyon), and the University of Corsica. As part of the virological surveillance of ARIs, Sentinelles physicians are asked to collect nasopharyngeal swabs or saliva samples from a sample of patients presenting with an ARI during their clinic visits. This surveillance makes it possible to identify respiratory viruses circulating in primary care (general practice and pediatrics), to describe confirmed cases for each of the circulating viruses, and to estimate the impact of each on general practice. This surveillance also allows for the evaluation of the effectiveness of vaccines against influenza and COVID-19.",[58,59,60,26,61,62,63],"Respiratory Tract Infections (RTI)","Influenza -Like Illness","Influenza","RSV Infections","Rhinovirus Infection","Metapneumovirus Infection","2026-06-03",{"date":66,"type":37},"2026-06-05",{"date":68,"type":20},"2026-05-15",{"date":70,"type":20},"2031-05-20",{"name":72,"class":73},"Institut National de la Santé Et de la Recherche Médicale, France","OTHER_GOV",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":81,"enrollmentInfo":82,"targetDuration":81,"studyType":55,"phases":4,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":4},"100636733","development-of-preterm-infants-born-during-the-covid-19-pandemic-100636733","NCT07569523","Development of Preterm Infants Born During the COVID-19 Pandemic","Estudio Del Desarrollo de Los niños Prematuros Nacidos Durante la Pandemia Por el COVID-19","Inclusion Criteria:\n\n* Preterm babies (\\\u003C34 weeks of gestation) born between March 2020 and December 2021 for case group).\n* Preterm babies (\\\u003C34 weeks of gestation) born between January 2023 to December 2024 (control group).\n* Babies who were admitted to the NICU of the Hospital de Sant Pau.\n* Babies who were followed up in External Consultations of the same hospital at least until their first year of age.\n\nExclusion Criteria:\n\n* Preterm infants ≥34 weeks or preterm born outside the periods described in the inclusion criteria.\n* Concurrent diagnosis of genetic pathology or major malformations.\n* Families who discontinued follow-up or did not attend scheduled appointments.","5 Years",{"count":83,"type":20},120,"This study aims to evaluate differences in cognitive and psychomotor development among preterm infants (born before 34 weeks of gestation) delivered during the COVID-19 pandemic at Hospital de la Santa Creu i Sant Pau, compared with a control group of preterm infants born at the same hospital.",[86,26],"Preterm Infant Development","2026-05-06",{"date":89,"type":37},"2026-05-11",{"date":91,"type":20},"2026-05",{"date":93,"type":20},"2029-12",{"name":95,"class":44},"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau",{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":103,"sex":16,"minAge":17,"maxAge":104,"enrollmentInfo":105,"targetDuration":4,"studyType":21,"phases":107,"briefSummary":109,"conditions":110,"keywords":111,"overallStatus":116,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":45},"100624969","phase-1-effect-of-cov2-vaccine-formulation-on-the-ability-to-generate-antibodies-against-coronavirus-that-causes-covid-19-100624969","NCT07416539","Effect of COV2 Vaccine Formulation on the Ability to Generate Antibodies Against Coronavirus That Causes COVID-19","A Phase 1a, Single-Blind, Randomized Comparative Clinical Trial Evaluating the Impact of Vaccine Formulation on the Safety and Immunogenicity of the COV2 Vaccine in Healthy Adults","Inclusion criteria\n\n* Has voluntarily signed the written informed consent\n* Male or female aged ≥18 to ≤75 years\n* Good general health based upon the results of the medical history, laboratory tests, physical examination, ENT clinical examination, and vital signs as assessed by the investigator\n* Prior vaccination with at least two doses of any COVID-19 vaccine with last dose obtained ≥180 days before the planned baseline (Day 0) visit\n* Has a personal smartphone, tablet or computer with internet access, and is considered willing and able to report the data in the ePRO and to comply with the reporting timelines\n* Willing and able to comply with the instructions to participants\n* Not of childbearing potential or willing and able to use a highly effective contraception method consistently and correctly during the entire trial\n\nExclusion criteria\n\n* Pregnant, planning to become pregnant, or breastfeeding women\n* Received any investigational drug \\\u003C 180 days prior baseline\n* Antigen positivity or PCR confirmed SARS-CoV-2 infection less than 180 days apart from screening or during screening and\u002For baseline\n* Any SARS-CoV vaccination was administrated \\\u003C 180 days prior the planned baseline (Day 0) visit\n* Any other vaccination within 60 days prior the planned baseline (Day 0) visit\n* Administration of immunoglobulins or blood products within 90 days prior baseline\n* Current use of immunosuppressant medication (except topical and inhaled steroids, which are permitted in indications not prohibited in the exclusion criteria)\n* Use of steroid nasal sprays within 30 days prior to screening\n* Use of any oral or nasal decongestants within 7 days prior to screening\n* Any confirmed or suspected immunodeficient state\n* Chronic respiratory diseases (except treatment -controlled asthma)\n* Severe chronic cardiovascular and endocrinological diseases (e.g., medicine or insulin treated diabetes), liver and renal insufficiency or serious psychiatric diseases\n\n  \\- Medication for elevated cholesterol or blood pressure or dietary treated diabetes or hypothyreosis are not exclusion criteria\n* Any diagnosed disease or abnormality in the nasal or upper respiratory tract, such as acute\u002Fchronic rhinosinusitis; nasal polyposis; mucosal pathology or tumor of nasal cavity, pharynx or nasopharynx; significant obstructive nasal deformity; recurrent epistaxis; sleep apnea; anosmia\n\n  \\- History of adenoidectomy and\u002For tonsillectomy are not exclusion criteria\n* Severe obesity (BMI ≥ 35)\n* Cancer treated within 5 years\n* Known allergy\u002Fhypersensitivity to any ingredients of the COV2 vaccine\n* Previous anaphylactic reaction\n* Any clinically significant abnormal finding in the screening laboratory tests\n* Inability to sign ICF or to understand and comply with trial related instructions and requirements\n* Individuals who are employees of, or directly affiliated with, the sponsor, or site staff or their immediate family members.",true,"75 Years",{"count":106,"type":20},20,[108],"PHASE1","This is a Phase 1a, single-country, single-centre, single-blinded, COV2 vaccine formulation randomized trial designed to investigate and compare the safety and immunogenicity of two COV2 vaccine formulations. COV2 is a nasal, investigational vaccine against COVID-19, based on a serotype 5 adenoviral vector producing modified SARS-CoV-2 spike protein.\n\nParticipants will receive one of the two COV2 formulations in two doses on Day 0 and Day 28.\n\nThis trial consists of two parts; Part 1 is a vaccination phase assessing safety and immunogenicity and Part 2 is a long-term immunogenicity follow-up assessing persistence of immune response.",[26,28],[112,113,114,115],"nasal vaccine","COVID-19","adenoviral vector-based vaccines","Sars CoV-2","RECRUITING","2026-02-18",{"date":119,"type":37},"2026-02-20",{"date":121,"type":37},"2026-02-10",{"date":123,"type":20},"2026-11",{"name":125,"class":126},"Rokote Laboratories Finland Oy","INDUSTRY",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":21,"phases":136,"briefSummary":138,"conditions":139,"keywords":4,"overallStatus":116,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":149},"100605014","phase-2-early-stage-trial-to-determine-a-safe-and-effective-dose-for-ratutrelvir-in-patients-with-mild-to-moderate-covid-19-100605014","NCT07157007","Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19","A Multicenter, Open-Label, Randomized Phase 2a Study to Evaluate Safety and Efficacy of Ratutrelvir and Standard of Care in Non-hospitalized Symptomatic Adult Participants With Mild to Moderate COVID-19","Inclusion Criteria:\n\n1. Confirmed SARS-CoV-2 infection for 120 h prior to randomization.\n2. Initial onset of signs\u002Fsymptoms attributable to COVID-19 within 5 days prior to randomization.\n3. At least one of the symptoms attributable to COVID-19 present within 24 hours prior to the Day 1 with the severity score of 1 or higher according to the following scoring system for the assessment of severity of:\n\nExclusion Criteria:\n\nMedical Conditions:\n\n1. History, current need for hospitalization or anticipated need for hospitalization for the medical treatment of COVID-19.\n2. Urgent or expected need for nasal high-flow oxygen therapy or positive pressure ventilation, invasive mechanical ventilation or ECMO.\n3. Known medical history of active liver disease .\n4. Receiving dialysis or history of moderate to severe renal impairment.\n5. Compromised immune system.\n6. Acute episode of chronic respiratory diseases, including bronchial asthma, chronic obstructive pulmonary disease within 30 days before screening.\n7. Suspected or confirmed concurrent active systemic infection..\n\n   Prior\u002FConcomitant Therapy:\n8. Has received or is expected to receive any dose of a SARS-CoV-2 vaccine within 4 months of screening and during the participation in the study.\n9. Concomitant use of any medications or substances that are strong inducers of CYP3A4",{"count":135,"type":20},90,[137],"PHASE2","This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19. It will also learn about the safety of drug Ratutrelvir. Participants will take a study drug as well as a standard therapy. A descriptive statistics will be used to present the study results.",[26],"2026-01-17",{"date":142,"type":37},"2026-01-21",{"date":144,"type":37},"2025-09-16",{"date":146,"type":20},"2026-03",{"name":148,"class":126},"Traws Pharma, Inc.",15,{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":156,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":16,"minAge":158,"maxAge":4,"enrollmentInfo":159,"targetDuration":4,"studyType":21,"phases":161,"briefSummary":163,"conditions":164,"keywords":4,"overallStatus":116,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":179},"100613120","assessement-of-effectiveness-of-seawater-nasal-sprays-on-sinonasal-symptoms-100613120","NCT07262450","Assessement of Effectiveness of Seawater Nasal Sprays on Sinonasal Symptoms","Real-word Study to Assess Effectiveness of Seawater Nasal Sprays on Sinonasal Symptoms","SeaBridge","Inclusion criteria:\n\n* Subject's age and medical condition in compliance with the intended use and population\n* Subjects who, from the investigator's judgement, should benefit from nasal wash in accordance with routine medical practice\n* Subjects with at least two nasal symptoms of intensity ≥ 3 (6 modalities intensity SNOT-22 rating-scale) among the following:\n\n  * Nasal blockage\u002Fnasal congestion\u002F stuffy nose;\n  * Runny nose;\n  * Need to blow\u002Fclear the nose;\n  * Sneezing;\n  * Thick nasal discharge\u002Fsecretions;\n  * Decreased sense of smell \u002Ftaste (replaced by \"noisy breathing\u002Fmouth breathing\" for infants)\n* Subjects with impaired nasal breathing (score ≥ 3, 6-modalities intensity rating-scale), induced by the presence of nasal symptoms\n* For acute indications (only): subjects with symptoms started not later than 72 hours prior to enrolment (Day 0).\n* For allergic rhinitis indication: perennial allergic rhinitis with and without seasonal allergic rhinitis\n* For post-surgery indication: septoplasty and rhinoseptoplasty.\n* Subject\u002Fparent willing to perform nasal wash following advices received from HCPs.\n* Subjects (or parents for babies and children) agreeing to follow the study requirements during the whole study period (up to 3 months).\n* Subject (or parent for baby and children) able to understand verbal and written local language and in capacity to fill-in questionnaire by himself.\n* Subject having daily access to internet to answer online questionnaire.\n* Subject or Parent\u002Flegal guardian of the subject has given freely and expressly her\u002Fhis informed consent.\n* Subject affiliated to the health social security system or beneficiary of an equivalent system\n\nNon-inclusion criteria:\n\n* Subject with contraindications according to each IFU.\n* Hypersensitivity or known allergy to any component of the investigational products.\n* Subject taking part in another clinical study or being in the exclusion period of another clinical study.\n* Subject already using nasal wash to manage his nasal symptoms.\n* Subject already included once in the study.\n* Subject with a member of his household already included in the study if still in the follow-up phase.\n* Subject deprived of liberty by administrative or judicial decision or under legal guardianship.","15 Days",{"count":160,"type":20},1065,[162],"NA","The purpose of this post-market clinical investigation is to assess in a real-life setting, the effectiveness, usage, tolerance, safety and satisfaction of 4 isotonic and hypertonic seawater-based CE-marked nasal sprays.\n\nThe main questions it aims to answer are:\n\n* Efficacy,\n* Safety,\n* Usage,\n* Satisfaction, in real-life usage among infants, children, adults and pregnant or breastfeeding women suffering from acute and chronic sinonasal pathologies. The 4 medical devices under investigation will be used in accordance with their intended use, target populations and medical indications.",[165,166,26,167,168,169],"URTI","Bronchiolitis","Allergic Rhinitis","Chronic Rhinosinusitis (CRS)","Post-surgery","2025-12-01",{"date":172,"type":37},"2025-12-03",{"date":174,"type":37},"2025-08-27",{"date":176,"type":20},"2026-08",{"name":178,"class":126},"Laboratoire de la Mer",32,{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":186,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":188,"targetDuration":4,"studyType":21,"phases":189,"briefSummary":190,"conditions":191,"keywords":4,"overallStatus":116,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":45},"100608100","phase-2-safety-and-effectiveness-of-a-remdesivir-treatment-to-prevent-severe-covid-19-in-kidney-transplant-patients-100608100","NCT07197164","Safety and Effectiveness of a Remdesivir Treatment to Prevent Severe COVID-19 in Kidney Transplant Patients","Safety and Efficacy of 10-day Course of Remdesivir to Prevent Severe COVID-19 in Asymptomatic or Paucisymptomatic SARS-COV-2-positive Kidney Transplant Recipients: a Single-arm Proof-of-concept Interventional Trial","COVIDKIDNEY","Inclusion Criteria:\n\n1. At least 18 years-old\n2. Patients with end-stage kidney disease that are included on the local kidney transplant waiting list who get an offer of a compatible organ and, subsequently, have a transplant procedure scheduled in the next 24 (+\u002F-) 12 hours, or patients with end-stage kidney disease that are planned to receive a non-cadaveric donor kidney transplant on the following 5 days.\n3. Have a positive SARS-CoV-2 nasopharyngeal PCR or RAT within 5 days prior to transplant surgery.\n4. Have previously received at least three SARS-CoV-2 vaccine doses, with a minimum time elapsed of 3 months since the last dose received.\n5. Are asymptomatic or have mild acute COVID-19 symptoms during the previous 5 days (headache, sore throat, cough, chest pain, nausea, diarrhea, fatigue, loss of smell or taste, myalgia) excluding fever in the previous 48 hours (\\>38ºC) or shortness of breath.\n6. Post-menopausal or fertile females (females who are not surgically sterile or postmenopausal defined as amenorrhea for \\>12 months) that agree to avoid pregnancy during the study. If sexually active fe-male; using highly effective contraceptive methods (hormonal contraception, intra-uterine device (IUD), or anatomical sterility in self or partner\\*) while on study treatment. All female volunteers must be willing to undergo urine pregnancy tests at time of enrollment.\n7. Having understood the information provided and capable of giving consent to participate in this trial by signing the Informed Consent document.\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding women, at time of enrollment\n2. Patients requiring supplementary oxygen at baseline or diagnosed with severe COPD or pulmonary fibrosis.\n3. Patients having any of the following at the screening period: i) O2 saturation below 94% on room air; ii) respiratory frequency of \\> 30bpm; or iii) Xray showing new-onset pulmonary infiltrates suggesting COVID-19 pneumonia.\n4. Patients having fever (\\>38ºC) in the last 48 hours or shortness of breath in the previous 5 days.\n5. Previous history of hypersensitivity, documented allergy or contraindications to receive remdesivir.\n6. ABO incompatible kidney transplant\n7. Desensitization therapy indicated as induction therapy for high immunological risk transplant with Donor Specific HLA Antibodies (DSA)\n8. Participants who receive different types of induction immunosuppression other than the standard induction protocols with lymphocyte- depleting agents (thymoglobulin or basiliximab).\n9. Active liver disease with AST or ALT \\>3 ULN, Total bilirubin ≥2 × ULN (for Gilbert's syndrome, direct bilirubin \\>ULN is exclusionary) within the past 3 months, or liver function impairment with Class B or C per Child Pugh classification.\n10. Suspected or confirmed concurrent active respiratory infection other than COVID-19 that may interfere with the evaluation of response to the study intervention.\n11. Any comorbidity requiring hospitalization and\u002For surgery within 7 days prior to study entry, or that is considered life threatening within 30 days prior to study entry, as determined by the investigator.\n12. Prior participation in this trial.\n13. Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.",{"count":149,"type":20},[137],"Since the start of the COVID-19 pandemic, the approach to solid organ transplantation has evolved. Transplants using organs (excluding lungs) from COVID-19-positive donors have shown short-term safety, but there is limited data on recipients who are SARS-CoV-2 positive. Currently, kidney transplants in such recipients are delayed until symptoms resolve and a negative PCR is preferred, despite the risks of prolonged dialysis and increased cold ischemia time.\n\nRecent data from the Omicron era suggest that early antiviral treatment may reduce complications. Immunosuppressive therapy might even help mitigate severe inflammatory responses. The proposed study aims to show that kidney transplantation can be safely performed in asymptomatic or mildly symptomatic COVID-19-positive recipients who begin antiviral treatment (remdesivir) within 24 hours before transplant and continue for 10 days. This could reduce waiting times and improve outcomes.\n\nRemdesivir is an antiviral safe for use in patients with low kidney function, including those on dialysis or post-transplant, with minimal side effects. The hypothesis is that this treatment strategy can prevent progression to severe COVID-19 and allow safe transplantation",[26,192,193],"Renal Transplant","SARS CoV 2 Infection","2025-09-26",{"date":196,"type":37},"2025-09-29",{"date":198,"type":37},"2025-09-01",{"date":200,"type":20},"2027-02-28",{"name":202,"class":44},"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia",{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":207,"acronym":4,"eligibilityCriteria":208,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":209,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":211,"conditions":212,"keywords":4,"overallStatus":116,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":223},"100595255","surveillance-assessment-and-detection-of-influenza-associated-respiratory-infections-in-hiv-positive-and-negative-individuals-in-lusaka-zambia-100595255","NCT07030075","SURVEILLANCE, ASSESSMENT AND DETECTION OF INFLUENZA ASSOCIATED RESPIRATORY INFECTIONS IN HIV POSITIVE AND NEGATIVE INDIVIDUALS IN LUSAKA, ZAMBIA","Inclusion Criteria:\n\n* i. age ≥18 years old ii. presenting with flu-like symptoms or acute respiratory infection with ≥2 to 7 days history of cough and \u002For sore throat and fever, +\u002F- sneezing, +\u002F- congestion, +\u002F- myalgia, +\u002F- fatigue, +\u002F- wheezing, shortness of breath)\\[55-57\\] iii. willing to share their HIV status or be tested iv. willing to share their COVID-19 vaccination status v. able and willing to give informed consent vi. willing to provide a nasal\u002F nasopharyngeal sample for testing as part of standard of care vii. willing to provide exhaled breath aerosol samples i.e. wear a mask and provide a breath sample viii. willing to fill a symptoms diary card for symptom tracking for 7 days ix. agree to be followed-up and attend study visits up to two weeks after study entry\n\nExclusion Criteria:\n\n* i. individuals who are unwilling to provide any reference standard samples such as the nasopharyngeal swabs ii. those with symptoms for \\>7 days, or iii. those unwilling or unable to provide informed consent",{"count":210,"type":20},594,"Background and rationale:The World Health Organisation (WHO), estimates influenza global deaths at 290,000 to 650,000 annually. Although influenza is mostly associated with upper respiratory tract infections (URTIs), its role in lower respiratory tract infections (LRTIs) and the associated poor clinical outcomes have been overlooked in sub-Saharan Africa. A study conducted in eight SSA countries estimated that 8.2% of cases and 2.8% of deaths from LRTIs were due to primary infection with influenza. Pneumonia and influenza-associated illness are responsible for 8.5% of respiratory deaths in Zambia. However, in routine practice, testing to distinguish between bacterial and viral etiology of RTIs is seldom done outside sentinel surveillance due to the high cost and lack of available testing options. This consequently underestimates viral RTIs in the population. It is particularly important to diagnose flu early on in vulnerable populations so that they receive timely and appropriate medical care. Although Zambia is a high HIV burden country with a prevalence of 11%, there is presently no study that has described the burden of influenza in the HIV positive population. This research study will address gaps in current scientific knowledge, providing key insights about the prevalence, circulating types, seasonality and associated clinical outcomes of influenza, RSV and SARS-CoV-2 infection in Zambia in the post COVID-19 era.\n\nObjectives Primary To determine the prevalence of influenza (A and\u002For B) infections in a high HIV burden setting in Lusaka, Zambia over one or more influenza seasons.\n\nSecondary\n\n1. To determine the prevalence of influenza co-infection with RSV and\u002For SARS-CoV-2\n2. To determine the clinical outcomes of influenza (A and\u002For B) infection among Zambian adults, with and without co-infection with RSV and COVID-19, by HIV and COVID-19 vaccination status.\n3. To evaluate the accuracy and yield of aerosol-based sampling for diagnosis of respiratory viruses (influenza, SARS-CoV-2, and RSV) compared to nasal\u002F nasopharyngeal swabs, for rapid diagnosis of infection among symptomatic individuals in Zambia.\n4. To evaluate the acceptability of exhaled breath aerosol (XBA) sampling for diagnosis and screening of respiratory infections of pandemic potential.\n\nStudy design and participants:\n\nPrimary objective and secondary objective 1:\n\nCross sectional surveillance study of individuals presenting with flu-like symptoms at two first level hospitals in Lusaka, Zambia. Recruitment of 594 participants will be done over the study period and participants will include both males and females presenting with 2-7 days of flu-like symptoms, able to provide informed consent, aged ≥18 years, with a known HIV status or willing to be tested, with a known COVID 19 vaccination status and available for symptom follow-up.\n\nSecondary objective 2:\n\nProspective follow up of participants enrolled in aim 1 for 14 days will be done to document clinical symptom progression and outcomes. Appropriate care will be provided to all participants within routine care services.\n\nSecondary objective 3 \\& 4:\n\nMixed methods approach. All patients enrolled under aim 1 will be requested to provide in addition to the routine nasopharyngeal sample, an aerosol-based sample for diagnostic accuracy and yield evaluation. We will also conduct an investigator-administered questionnaire to ascertain end-user experience and preferences for either sampling method.\n\nLocation Zambia (Kanyama and Chawama sub-districts) Duration April 2025 to November 2026 (Participant enrolment duration)",[60,213,26],"RSV","2025-06-12",{"date":216,"type":37},"2025-06-19",{"date":218,"type":37},"2025-05-20",{"date":220,"type":20},"2027-01",{"name":222,"class":44},"Centre for Infectious Disease Research in Zambia",2,{"id":225,"slug":226,"hasResults":11,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":4,"eligibilityCriteria":230,"healthyVolunteers":103,"sex":16,"minAge":17,"maxAge":231,"enrollmentInfo":232,"targetDuration":4,"studyType":21,"phases":234,"briefSummary":236,"conditions":237,"keywords":238,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":45},"100575162","early-phase-1-safety-and-immunogenicity-evaluation-of-the-recombinant-flagellin-protein-adjuvant-100575162","NCT06768697","Safety and Immunogenicity Evaluation of the Recombinant Flagellin Protein Adjuvant","Safety and Immunogenicity Evaluation of the Recombinant Flagellin Protein Adjuvant in the SARS-CoV-2 Subunit Mucosal Vaccine","Inclusion Criteria:\n\n1. The subjects are healthy individuals aged between 18 and 65 years old (inclusive), with no gender preference, ensuring an appropriate gender ratio.\n2. Have received 2-3 doses of COVID-19 inactivated vaccine, and the last dose was administered more than 6 months ago.\n3. Have not been infected with COVID-19 within 3 months.\n4. Capable of being used in conjunction with nasal sprays, and also suitable for nasal irrigation, saliva collection, and blood collection.\n5. Male subjects and their partners, or female subjects, must agree to adopt one or more non-drug contraceptive measures (such as complete abstinence, condoms, intrauterine devices, partner sterilization, etc.) during the trial period and for six months after the trial ends, and they must not have plans for sperm donation or egg donation.\n6. The subjects fully understand the purpose, nature, methods, and possible adverse reactions of the trial, voluntarily participate in the trial, and sign the informed consent form.\n7. The subject is able to communicate effectively with the researcher and complete the study in accordance with the protocol.\n\nExclusion Criteria:\n\n1. Active or suspected viral, bacterial, fungal, or parasitic infections, including herpes, shingles, or cold sores, within 14 days prior to screening.\n2. History of recurrent infections of unknown causes; or use of systemic antibiotics within 90 days prior to drug administration.\n3. Individuals with malignant tumors or a history of malignant tumors, except for non-melanoma skin cancer that has been cured for more than 3 years.\n4. Nasal malformation, trauma, or other reasons that make it impossible to use nasal sprays.\n5. Individuals with a history of allergy to biological agents or any drug components; individuals with a history of allergies, such as asthma, aspergillus infection, allergic rhinitis, etc., who have been determined by researchers to be unsuitable for enrollment.\n6. Screen for outpatient or inpatient history of clinically significant chronic or acute disease symptoms within the previous 3 months, and ensure no surgical plans during the study period.\n7. Previous tests have found HIV-Ab positive, HCV positive, and anti-syphilis helical-specific antibody positive (please consult the subject).\n8. Individuals with abnormal vital signs (refer to normal range: systolic blood pressure 90\\~139mmHg, diastolic blood pressure 60\\~89mmHg, pulse rate 55-100 beats\u002Fmin; body temperature (ear temperature) 35.4-37.7℃; respiratory rate 16-20 breaths\u002Fmin) or abnormal electrocardiogram (QTcB≥450 ms, QTcB= QT\u002FRR0.5) or clinically significant abnormalities in physical examination, laboratory tests (subject to the judgment of the clinical research doctor).\n9. Screen for the use of other medications, including prescription or non-prescription drugs, and herbal remedies, within the previous 4 weeks.\n10. Screen for individuals who have received vaccination within the previous 4 weeks or plan to receive vaccination during the study period.\n11. Individuals with a history of significant allergic reactions (anaphylaxis or angioedema) to any products (such as food and drugs), and known to be allergic to the test drug, its excipients, or similar drugs.\n12. Participate in any other drug clinical trials within 3 months before screening or within 5 half-lives of other clinical trial drugs (choose the longer time period).\n13. Exclude individuals who have donated plasma or whole blood exceeding 200 mL within the previous 3 months, except during menstruation.\n14. Individuals who abuse drugs or have used soft drugs (such as marijuana) within the past 3 months, or have consumed hard drugs (such as cocaine, phencyclidine, etc.) within the year prior to the trial; or individuals who test positive for drug abuse in urine screening (including methamphetamine, ketamine, MDMA, marijuana, morphine).\n15. Individuals who are alcoholics or have regularly consumed alcohol within the 6 months prior to the trial, with an average weekly alcohol intake exceeding 14 units (1 unit of alcohol is equivalent to approximately 360 mL of beer, 45 mL of spirits with a 40% alcohol content, or 150 mL of wine), or those who cannot abstain from alcohol during the trial period (interview).\n16. Subjects who have smoked an average of more than 5 cigarettes per day or used other nicotine-containing products (such as nicotine patches, nicotine gum, e-cigarettes, etc.) more than 5 times per day on average within the previous 3 months, or who cannot stop using any tobacco-related products during the trial period.\n17. Those who have previously or currently suffered from any clinically severe diseases of the circulatory system, endocrine system, nervous system, digestive system, respiratory system, urogenital system, hematology, immunology, psychiatry, or metabolic abnormalities, or any other diseases that may interfere with the results of the trial.\n18. Use other medications, including prescription or non-prescription drugs, and Chinese herbal medicine, from the screening date to D1.\n19. Women who are pregnant, breastfeeding, or may become pregnant.\n20. Clinical diagnosis of any autoimmune disease or rheumatic disease.\n21. The patient's blood COVID-19 specific IgG antibody is greater than 1×10e4.\n22. Any situation that other researchers consider unsuitable for participation in the study.\n\n    \\-","65 Years",{"count":233,"type":20},60,[235],"EARLY_PHASE1","The goal of this clinical trial is to learn if the SARS-CoV-2 subunit mucosal vaccine with the recombinant flagellin protein adjuvant works to Prevent COVID-19 infection. It will also learn about the Safety and immunogenicity of the vaccine.",[26],[239,240,241,242,243],"adjuvant","novel adjuvant","flagellin","mucosal vaccine","SARS-CoV-2","2025-01-06",{"date":246,"type":37},"2025-01-10",{"date":248,"type":20},"2024-12-30",{"date":250,"type":20},"2025-12-30",{"name":252,"class":73},"Shanghai Public Health Clinical Center"]